Blencowe Resources: Aspiring to become one of the largest graphite producers in the world. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAMP.L Regulatory News (AMP)

  • There is currently no data for AMP

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

IP License Agreements

5 May 2009 07:00

RNS Number : 5962R
Amphion Innovations PLC
05 May 2009
 



Amphion Innovations plc Partner Company, DataTern, Signs  

Three IP License Agreements worth $1.65m

London and New York5 May 2009 - Amphion Innovations plc (LSE: AMP) ("Amphion"), the developer of medical and technology businesses, today announces that DataTern, Inc., has signed non-exclusive intellectual property license agreements with three leading international corporations for a total of $1.65 million. DataTern has signed seven licenses since it commenced licensing of this product in June 2008, generating total revenues of approximately $7 million. DataTern has now licensed its intellectual property into the financial, credit card, retail, leisure, healthcare, and software industries.

Joseph Flicek, DataTern's Chief Executive Officer, said, "We have made rapid progress in a relatively short period of time, demonstrating the value that can be extracted from our intellectual property portfolioWe believe there are a large number of potential licensees in a broad spectrum of industries for our IP. Currently, we are in active discussions with six other major corporations and we continue to add to this list."

DataTern, Inc., wholly owned by Amphion Innovations plc, was established in order to commercialise selected intellectual property opportunities in partnership with Amphion's Partner Companies.

Richard Morgan, Chief Executive Officer of Amphion, said, "Today's announcement demonstrates the value that Amphion can generate for its shareholders through monetising our intellectual property.  Wcontinue to add further patents and software though the activities of DataTern and our Partner Companies and we look forward to signing further license agreements."

For further information please contact

Amphion Innovations Charlie Morgan +1 212 210 6224

Cardew GroupTim Robertson/ Jamie Milton/ Matthew Law +44 20 7930 0777

Charles Stanley (Nominated Adviser) Mark Taylor/ Freddy Crossley +44 20 7149 6000

About Amphion Innovations plc

Amphion (LSE: AMP) builds shareholder value in high growth companies in the medical and technology sectors, by using a focused, hands-on company building approach, based on decades of experience in both the US and UK. Amphion has a significant shareholding in eight Partner Companies, developing proven technologies targeting substantial commercial marketplaces, each in excess of $1 billion. Each Partner Company is chosen with the goal of achieving an exit valuation in excess of $100 million.

On the web: www.amphionplc.com 

About DataTern, Inc.

DataTern owns and develops critical technology that provides next generation software solutions for its customers. DataTern's patented product offerings include ObjectSpark® Technologies, which allow customers to develop their own customised data service layers, making the company's offerings valuable to most industries, including automotive, banking, chemical, communications, financial, government, healthcare, insurance, pharmaceutical, trading, and many others.

Non-exclusive licenses for DataTern's technologies and patents are available on reasonable and non-discriminatory terms. For licensing terms, please contact info@datatern.com.

On the web: www.datatern.com 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
AGRABMBTMMJMBML
Date   Source Headline
31st Dec 20191:15 pmRNSAmphion Innovations
31st Dec 201912:36 pmRNSCancellation of trading on AIM
20th Nov 20197:00 amRNSDirectors' Dealings and Business Update
18th Oct 20197:00 amRNSSettlement of loan facility
11th Oct 20197:01 amRNSPolarean notes statement from Amphion Innovations
11th Oct 20197:00 amRNSSale of Partner Company Shares
3rd Oct 20197:00 amRNSSale of Partner Company Shares
25th Sep 20197:00 amRNSAmended Terms on Loan Facility
10th Sep 20194:56 pmRNSSale of Partner Company Shares
9th Aug 20194:14 pmRNSStatement on Amphion Innovations
9th Aug 20194:14 pmRNSDirectorate Change
9th Aug 20193:51 pmRNSSale of Partner Company Shares
1st Jul 20197:30 amRNSSuspension - Amphion Innovations Plc
27th Jun 20193:00 pmRNSAnnual Report and Accounts Update
14th Jun 20199:04 amRNSHolding(s) in Company
12th Jun 20197:00 amRNSLoan facility update
31st May 201910:28 amRNSHolding(s) in Company
20th May 20196:14 pmRNSHolding(s) in Company
1st Apr 20194:40 pmRNSSecond Price Monitoring Extn
1st Apr 20194:35 pmRNSPrice Monitoring Extension
1st Apr 20197:00 amRNSUpdate on Loan Facility
20th Mar 20197:00 amRNSHolding(s) in Company
19th Mar 20192:33 pmRNSSale of Partner Company Shares
18th Mar 20192:00 pmRNSPrice Monitoring Extension
15th Mar 20197:01 amRNSHolding(s) in Company
15th Mar 20197:00 amRNSSale of Partner Company Shares
11th Mar 20194:41 pmRNSAmended Terms on Loan Facility
26th Feb 20197:00 amRNSConvertible Promissory Note Extended
14th Feb 20198:00 amRNSStatement re. Motif Bio plc
7th Feb 20199:40 amRNSStmnt re Share Price Movement
1st Feb 20197:00 amRNSAppointment of Joint Broker
21st Jan 20197:00 amRNSWellGen Finalises License Agreement
11th Dec 20187:05 amRNSInvestment in Polarean & Loan Facility Repayment
16th Oct 20187:00 amRNSExtended Repayment and Draw Down on Loan Facility
28th Sep 20187:00 amRNSHalf-year Report
5th Sep 20187:00 amRNSBoard Change
23rd Aug 20183:20 pmRNSPolarean update
21st Aug 20187:15 amRNSMotif Bio notes statement from Amphion Innovations
21st Aug 20187:00 amRNSSale of Partner Company Shares
1st Aug 20184:47 pmRNSResult of AGM
29th Jun 20187:00 amRNSDirectorate Change
26th Jun 20187:00 amRNSFinal Results
23rd May 20187:00 amRNSMotif Bio notes statement from Amphion Innovations
23rd May 20187:00 amRNSSale of Partner Company Shares
20th Apr 20187:00 amRNSDirectorate Change
29th Mar 20187:00 amRNSAIM Admission & First Day of Dealings
29th Mar 20187:00 amRNSUpdate on Polarean Imaging IPO
26th Mar 20187:31 amRNSUpdate on Polarean Imaging proposed AIM IPO
2nd Mar 20187:00 amRNSConvertible promissory note extended to December
10th Jan 20185:09 pmRNSDirector dealing

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.